Company: EDSA
Filing Date: 2025-08-08
Form Type: 10-Q
Source: 0001171843-25-005236
Chunk: 3

Company: Edesa Biotech, Inc.
Filing Date: 2025-08-08
Form: 10-Q
Item: Part I, Item 8
Chunk 3
---
September 30, 2027

			101,172

			September 30, 2028

			101,172

			September 30, 2029

			101,172

			Thereafter

			1,572,988

			$
			2,002,969

4. Right-of-Use Lease with Related Party

The Company leases a facility used for executive offices from a related company. The original lease expired in December 2022 and the Company executed a two-year extension through December 2024. The Company extended the lease until November 30, 2025, and upon expiry, the arrangement will be month to month and either party will have the right to terminate on 30 days’ notice.

8

The components of right-of-use lease cost were as follows:

			Three Months Ended 

			Nine Months Ended 

			June 30, 2025

			June 30, 2024

			June 30, 2025

			June 30, 2024

			Right-of-use lease cost, included in general and administrative on the Statements of Operations

			$
			-

			$
			19,299

			$
			17,885

			$
			59,208

Lease terms and discount rates were as follows:

			June 30, 2025

			September 30, 2024

			Remaining lease term (months):

			0

			3

			Estimated incremental borrowing rate:

			9.2
			%

			9.2
			%

Cash flow information was as follows:

			Nine Months Ended 

			June 30, 2025

			June 30, 2024

			Cash paid for amounts included in the measurement of right-of-use lease liabilities, included in accounts payable and accrued liabilities on the Statements of Cash Flow.

			$
			17,885

			$
			59,732

5. Commitments

Research and other commitments

The Company has commitments for contracted research organizations who perform clinical trials for the Company’s ongoing clinical studies and other service providers. Approximate aggregate future contractual payments at June 30, 2025 are as follows:

			Year Ending

			September 30, 2025

			$
			234,000

			September 30,